Myeloma

The agency granted accelerated approval to Pepaxto in combination with dexamethasone in adult patients with relapsed or refractory multiple myeloma, who received at least four prior lines of therapy.

Results from the phase 2 KarMMa trial showed that 73% of patients had a response to the CAR-T cell therapy, including 33% who experienced a complete response or better.

The Food and Drug Administration has had a busy winter so far, approving several new agents to treat a variety of cancers. Here are seven recent approvals that patients with cancer may have missed.

Quality of life improved in patients treated with Darzalex, Revlimid and dexamethasone compared with Revlimid and dexamethasone, and were present regardless of age, functional status and the depth of their treatment response.

Melflufen with dexamethasone was an effective treatment option for patients with relapsed or refractory multiple myeloma previously treated with a specific chemotherapy drug and/or an anti-CD38 monoclonal antibody.

A caregiver discusses with her granddaughter the cancer diagnosis and treatment of a loved one.

The Food and Drug Administration lifted a clinical hold on the MELANI-01 trial, evaluating UCARTCS1A, a CAR T-cell product in patients with relapsed or refractory multiple myeloma.

In an interview with CURE®, Dr. Irene M. Ghobrial discussed smoldering myeloma, a precursor condition that may progress to multiple myeloma, how to proceed if diagnosed with the condition and the available opportunities to participate in clinical trials to learn more.

Here are the top 10 episodes of the “CURE Talks Cancer” podcast from 2020.

This treatment strategy contributed to a median progression-free survival of 13.93 months compared with 9.46 months in those treated with Velcade and dexamethasone.

This treatment regimen of Xpovio with Velcade, approved for patients with multiple myeloma previously treated with at least one therapy, provides another option for patients with multiple myeloma to potentially close the treatment gap.

Advancements in the diagnosis and staging of multiple myeloma continue to shape treatment decisions and improve outcomes.

In an interview with CURE®, Dr. Giada Bianchi provides patients an overview of myeloma, including symptoms and risk factors of the disease people should look out for.

The complexity of multiple myeloma can make it difficult to treat, but with complexity comes more avenues for researchers to explore what treatments work best. Recently, CURE® spoke with an expert from Dana-Farber Cancer Institute on what patients can expect to see from the clinical setting.

View the full CURE®Educated Patient® Multiple Myeloma Summit here!

The phase 3 trial found that this treatment improves progression-free survival (PFS) during 18.7 months of follow-up, although patients treated with Venclexta (venetoclax) a had increased mortality rates compared with those treated with placebo.

Evolving standards of care in newly diagnosed multiple myeloma (MM) have given patients a wider variety of possibilities but can also be disconcerting. In a presentation during CURE®’s Educated Patient® Multiple Myeloma Summit, Dr. Clifton Mo, of Dana-Farber Cancer Institute, explores the treatment landscape and breaks down what these different options can offer patients.

A roundup of the latest news and updates for patients with myeloma from CURE®.

A meta-analysis of six clinical trials showed that standard treatment regimens for high-risk multiple myeloma may be more effective at delaying disease progression if they are given in combination with the targeted drug Darzalex (daratumumab).

Not everyone with myeloma needs to be treated right away, but when they do, there are some important upfront considerations for patients and providers.

Finding the best care team can make all the difference for patients with diseases like multiple myeloma.

Specific disease characteristics of, and treatments for, multiple myeloma were not associated with increased mortality risk in patients with multiple myeloma who developed COVID-19, according to data published in Journal of Hematology & Oncology.

The data demonstrated that the addition of Ninlaro to Revlimid and dexamethasone led to a 13.5-month increase in median progression-free survival, compared with placebo. However, the data failed to meet the threshold for statistical significance.

Forty percent of patients with triple-refractory multiple myeloma achieved a response after receiving 60 millicurie (a unit of radioactivity) or greater of CLR 131.

When compared with the standard of care triplet regimen of Velcade, Revlimid and dexamethasone, the combination of Kyprolis, Revlimid and dexamethasone did not demonstrate superior treatment results in patients with newly diagnosed multiple myeloma.

There have been several drug approvals and updates from the Food and Drug Administration (FDA) in the cancer space over the last several weeks.

The Food and Drug Administration granted a priority review to the new drug application for melflufen in combination with dexamethasone for adults with relapsed and refractory multiple myeloma (RRMM) who had previously received multiple lines of therapy.

In addition to improving progression-free survival, researchers have found single-agent Ninlaro (ixazomib) to be a tolerable option in patients with newly diagnosed multiple myeloma who have also already undergone an autologous stem cell transplant.